|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
gp130 / CD130 / IL6ST Antibody Datasheet
|Order or Inquire for gp130 / CD130 / IL6ST Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.00245 ng/well in ELISA|
gp130 / CD130 / IL6ST Antibody Product Information
Recombinant Mouse gp130 / CD130 / IL6ST protein (Catalog#50135-M08H)
|Antibody Type :||Rabbit Polyclonal Antibody ( Antibody Purification Platform )|
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
Produced in rabbits immunized with purified, recombinant Mouse gp130 / CD130 / IL6ST (rM gp130 / CD130 / IL6ST; Catalog#50135-M08H; NP_034690.3; Met 1-Glu 617). Total IgG was purified by Protein A affinity chromatography.
gp130 / CD130 / IL6ST Antibody Usage Guide
Mouse gp130 / CD130 / IL6ST
|Western blot :||This antibody can be used at 1-2 μg/mL with the appropriate secondary reagents to detect Mouse IL6ST in WB.|
|Direct ELISA :||This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect Mouse IL6ST. The detection limit for Mouse IL6ST is approximately 0.00245 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
gp130 / CD130 / IL6ST Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|gp130/CD130||Human||gp130/CD130/Fc Protein, Recombinant||10974-H03H|
|gp130/CD130||Mouse||gp130/CD130 Protein, Recombinant||50135-M03C|
|gp130/CD130||Mouse||gp130/CD130 Protein, Recombinant||50135-M08H|
|gp130/CD130||Rat||gp130/CD130 Protein, Recombinant||80030-R06H|
|gp130/CD130||Rat||gp130/CD130 Protein, Recombinant||80030-R08H|
|gp130/CD130||Mouse||IL6ST / gp130 / CD130 Protein, Recombinant||50135-M03H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Mouse gp130/CD130||WB, ELISA||gp130 / CD130 / IL6ST Antibody||50135-RP01|
|Mouse gp130/CD130||WB, ELISA||gp130 / CD130 / IL6ST Antibody (Antigen Affinity Purified)||50135-RP02|
|Rat gp130/CD130||WB, ELISA||gp130 / CD130 / IL6ST Antibody||80030-MM04|
|Rat gp130/CD130||WB, ELISA||gp130 / CD130 / IL6ST Antibody||80030-MM08|
gp130 / CD130 / IL6ST Antibody Background
Glycoprotein 130 (gp130), also known as IL6ST, IL6R-beta and CD130, is a common signal-transducing molecule shared by the functional receptor complexes of the IL-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor (LIF), granulocyte colonystimulating factor, ciliary neurotrophic factor, and cardiotrophin-1). It belongs to the class I cytokine receptor family, and was found in tissues such as brain, heart, thymus, spleen, kidney, lung and liver. Mouse gp130 contains five fibronectin type-III domains, and one Ig-like C2-type (immunoglobulin-like) domain. gp130 is an important part of many different types of signaling complexes. It binds to IL6/IL6R (alpha chain) complex, resulting in the formation of high-affinity IL6 binding sites, and transduces the signal. This complex of 3 proteins then homodimerizes to form a hexameric complex which can produce downstream signals. Inactivation of gp130 is lethal to mice. The mice homozygous for a knock-in mutation in gp130 that leads to gp130-dependent signal transducers and activators of transcription (STAT) 1/3 hyperactivation develop a broad spectrum of hematopoietic abnormalities, including splenomegaly, lymphadenopathy, and thrombocytosis. gp130 is also involved in various human diseases, such as liver disease, coronary artery disease and myocardial infarction. Furthermore, gp130 is widely expressed in breast cancer cell lines and primary tumors, thus it have been implicated in constitutive STAT3 activation in breast cancer.
- Saito, M. et al., 1992, J Immunol. 148 (12): 4066-4071.
- Murakami, M. et al., 1993, Science. 260 (5115): 1808-1810.
- Yoshida, K. et al., 1996, Proc Natl Acad Sci. 93 (1): 407-411.
- Selander, K.S. et al., 2004, Cancer Res. 64 (19): 6924-6933.
- Jenkins, B.J. et al., 2005, Blood. 105 (9): 3512-3520.
- Luchtefeld, M. et al., 2007, J Exp Med. 204 (8): 1935-1944.